Lario Therapeutics

Lario Therapeutics is a biopharmaceutical company focused on developing precision medicines for severe neurological disorders. The company targets severe developmental and epileptic encephalopathies, as well as neurodegenerative disorders, using a validated, precision medicine approach. Lario's pipeline is rapidly advancing, beginning with genetically validated targets that promise broad therapeutic potential. This approach aims to slow the progression of devastating early childhood syndromes and adult neurological disorders. The company operates in the biopharmaceutical market and serves patients suffering from severe neurological conditions. Lario Therapeutics generates revenue through the development and commercialization of its proprietary treatments. The company has been recognized for its excellence in making a difference in the field of genetic epilepsies, receiving the Forum Award for Excellence Company Making a Difference 2023 from the Loulou Foundation.

Keywords: precision therapeutics, neurological disorders, genetic epilepsies, biopharmaceutical, neurodevelopmental syndromes, disease-modifying treatments, genetically validated, developmental encephalopathies, neurodegenerative disorders, proprietary treatments.